ProQR Therapeutics N.V. (PRQR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Quarterly

0 2.5M 5M 7.5M Q2 '21: 243K Q3 '21: 872K Q4 '21: 239K Q1 '22: 1.1M Q2 '22: 930K Q3 '22: 814K Q4 '22: 720K Q1 '23: 655K Q2 '23: 1.2M Q3 '23: 1.4M Q4 '23: 3.3M Q1 '24: 4.5M Q2 '24: 6.3M Q3 '24: 3.8M Q4 '24: 4.3M Q1 '25: 4.5M Q2 '25: 3.8M Q3 '25: 2.9M Q4 '25: 4.7M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit Quarterly

-21M -14M -7M 0 7M 14M 21M Q2 '21: -13.6M Q3 '21: -14.8M Q4 '21: -17.5M Q1 '22: -17.1M Q2 '22: -15.9M Q3 '22: -19.9M Q4 '22: -13M Q1 '23: -9.4M Q2 '23: -8.8M Q3 '23: -7.4M Q4 '23: -9.2M Q1 '24: -8.3M Q2 '24: -3.8M Q3 '24: -8.9M Q4 '24: -10.2M Q1 '25: -11M Q2 '25: -12.4M Q3 '25: -11.3M Q4 '25: -9.1M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q2 '17: -10.2M Q1 '18: -9.9M Q2 '18: -7.7M Q3 '18: -5.9M Q4 '18: -12.8M Q1 '19: -14.7M Q2 '19: -11.8M Q3 '19: -13.4M Q4 '19: -17.4M Q1 '20: -16.5M Q2 '20: -3.4M Q3 '20: -10.9M Q4 '20: -11.7M Q1 '21: -12.1M Q2 '21: -13.2M Q3 '21: -14.6M Q4 '21: -17.3M Q1 '22: -17M Q2 '22: -15.8M Q3 '22: -19.8M Q4 '22: -12.5M Q1 '23: -9.4M Q2 '23: -8.8M Q3 '23: -7.4M Q4 '23: -6.3M Q1 '24: -8.1M Q2 '24: -3.6M Q3 '24: -8.7M Q4 '24: -10.1M Q1 '25: -10.8M Q2 '25: -12.2M Q3 '25: -11.3M Q4 '25: -9.1M Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q2 '17: -11.4M Q1 '18: -10.7M Q2 '18: -7.4M Q3 '18: -6M Q4 '18: -13M Q1 '19: -14.2M Q2 '19: -11.7M Q3 '19: -12.2M Q4 '19: -18.6M Q1 '20: -16.1M Q2 '20: -4.1M Q3 '20: -13.2M Q4 '20: -13.2M Q1 '21: -12.6M Q2 '21: -15.8M Q3 '21: -15.1M Q4 '21: -18.2M Q1 '22: -14.1M Q2 '22: -13.5M Q3 '22: -23.3M Q4 '22: -13.3M Q1 '23: -8.9M Q2 '23: -8M Q3 '23: -5.4M Q4 '23: -5.5M Q1 '24: -7.7M Q2 '24: -2.7M Q3 '24: -8.1M Q4 '24: -9.3M Q1 '25: -10.1M Q2 '25: -12.2M Q3 '25: -11M Q4 '25: -8.9M Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Cost of Revenue Quarterly

0 8M 16M 24M Q2 '17: 10.4M Q1 '18: 10.4M Q2 '18: 8.6M Q3 '18: 8.9M Q4 '18: 14.2M Q1 '19: 15.2M Q2 '19: 12.4M Q3 '19: 14M Q4 '19: 17.8M Q1 '20: 16.7M Q2 '20: 12M Q3 '20: 11.1M Q4 '20: 11.9M Q1 '21: 12.2M Q2 '21: 13.9M Q3 '21: 15.7M Q4 '21: 17.8M Q1 '22: 18.3M Q2 '22: 16.9M Q3 '22: 20.7M Q4 '22: 13.7M Q1 '23: 10.1M Q2 '23: 10.1M Q3 '23: 8.8M Q4 '23: 12.5M Q1 '24: 12.7M Q2 '24: 10.1M Q3 '24: 12.7M Q4 '24: 14.5M Q1 '25: 15.6M Q2 '25: 16.2M Q3 '25: 14.2M Q4 '25: 13.8M Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Operating Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q2 '17: -9.8M Q1 '18: -9.7M Q2 '18: -5.4M Q3 '18: -4.3M Q4 '18: -9.1M Q1 '19: -12.4M Q2 '19: -10.9M Q3 '19: -8.8M Q4 '19: -12M Q1 '20: -15M Q2 '20: -10.5M Q3 '20: -9.8M Q4 '20: -11.8M Q1 '21: -11.8M Q2 '21: -10M Q3 '21: -8.1M Q4 '21: 3.8M Q1 '22: -20.5M Q2 '22: -14.8M Q3 '22: -15.4M Q4 '22: -17.8M Q1 '23: 44.7M Q2 '23: -10.3M Q3 '23: -7.5M Q4 '23: -5.3M Q1 '24: -15.1M Q2 '24: -6.3M Q3 '24: -5.7M Q4 '24: -9.3M Q1 '25: -15.8M Q2 '25: -11.4M Q3 '25: -12.2M Q4 '25: -13.4M Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q2 '17: -9.9M Q1 '18: -9.7M Q2 '18: -5.6M Q3 '18: -4.4M Q4 '18: -9.1M Q1 '19: -12.6M Q2 '19: -11M Q3 '19: -8.8M Q4 '19: -12.2M Q1 '20: -15.2M Q2 '20: -10.8M Q3 '20: -10.1M Q4 '20: -11.9M Q1 '21: -11.8M Q2 '21: -10M Q3 '21: -8.2M Q4 '21: 3.6M Q1 '22: -20.7M Q2 '22: -15.1M Q3 '22: -15.6M Q4 '22: -17.8M Q1 '23: 44.6M Q2 '23: -10.6M Q3 '23: -7.8M Q4 '23: -5.9M Q1 '24: -15.9M Q2 '24: -6.5M Q3 '24: -5.9M Q4 '24: -9.5M Q1 '25: -16M Q2 '25: -11.5M Q3 '25: -12.4M Q4 '25: -13.9M Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '17: 24M Q2 '18: 31.9M Q3 '18: 33.4M Q1 '19: 38.9M Q2 '19: 38.9M Q3 '19: 38.9M Q4 '19: 47.4M Q1 '20: 49.9M Q2 '20: 50M Q3 '20: 50.1M Q4 '20: 50.2M Q1 '21: 50.8M Q2 '21: 66.1M Q3 '21: 68.3M Q4 '21: 71.2M Q1 '22: 71.4M Q2 '22: 71.4M Q3 '22: 71.4M Q1 '23: 80.9M Q2 '23: 80.9M Q3 '23: 81M Q1 '24: 81.6M Q2 '24: 81.7M Q3 '24: 81.7M Q1 '25: 105.3M Q2 '25: 105.3M Q3 '25: 105.3M Q3 '18 Q4 '19 Q4 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '19: -1.36 Q1 '20: -1.32 Q2 '20: -1.10 Q3 '20: -1.05 Q4 '20: -0.92 Q1 '21: -0.85 Q2 '21: -1.01 Q3 '21: -0.97 Q4 '21: -0.97 Q1 '22: -0.92 Q2 '22: -0.87 Q3 '22: -0.98 Q4 '22: -0.90 Q1 '23: -0.81 Q2 '23: -0.72 Q3 '23: -0.46 Q4 '23: -0.35 Q1 '24: -0.33 Q2 '24: -0.26 Q3 '24: -0.29 Q4 '24: -0.31 Q1 '25: -0.32 Q2 '25: -0.41 Q3 '25: -0.41 Q4 '25: -0.40 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.